Esperion’s LDL drug flies through phase 2 as add-on treatment

greenlight
Esperion expects to file NDAs for bempedoic acid as a standalone therapy and as a combination with Zetia in the first quarter of 2019. (Nadine Doerlé)

Esperion’s bempedoic acid met the primary endpoint in a phase 2 study, in which it was administered to patients already taking a PCSK9 inhibitor to lower their cholesterol.

The eight-week trial involved 58 patients with hypercholesterolemia who received a once daily, 180-mg dose of bempedoic acid or placebo on top of a stable background therapy of Repatha, a PCSK9 blocker from Amgen.

Topline data show the treatment reduced LDL cholesterol levels by 30%, meeting its primary endpoint, the company said. Specifically, patients treated with bempedoic acid had a 27% decrease in LDL levels, while patients who received placebo had a 3% increase in LDL. In addition, the treatment group had a 34% drop in high-sensitivity C-reactive protein (hsCRP), a biomarker of inflammation linked to heart disease, while the placebo group had only a 2% reduction.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

“Bempedoic acid has previously demonstrated the ability to complement currently available standard-of-care oral LDL-C lowering therapies, and the results of this Phase 2 study show that bempedoic acid can also be safely and effectively used in patients who require additional LDL-C lowering despite taking an injectable PCSK9 inhibitor,” said Esperion CEO Tim Mayleben. “These Phase 2 results provide consistent evidence and further support that bempedoic acid is poised to become the broadly accessible, complementary, once-daily, oral LDL-C lowering therapy that is appealing to patients, physicians and payers.” 

The news comes barely three weeks after the treatment made the grade as a monotherapy in phase 3, where it lowered LDL levels 23% from baseline, compared to a 5% increase observed in patients on placebo. The trial involved 269 patients with atherosclerosis, or patients who are at high risk of atherosclerosis whose cholesterol cannot be controlled with lipid-modifying drugs, such as Merck’s Zetia, or the lowest approved starting dose of a statin.

Esperion has also tested bempedoic acid in combination with statins—it reported in August that a combo of bempedoic acid with the active ingredients in Merck’s Zetia and Pfizer’s Lipitor lowered LDL by 64%, outshining results achieved by a Zetia/Lipitor pairing in other studies. The company expects to file NDAs for bempedoic acid as a standalone therapy and as a combination with Zetia in the first quarter of 2019.

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.